Core Insights - BioRestorative Therapies, Inc. has appointed Crystal Romano to lead its global commercial operations and innovation, marking a significant step in the company's growth strategy [1][3] Company Overview - BioRestorative is focused on regenerative medicine, particularly stem cell-based therapies and products, with two main clinical development programs targeting disc/spine disease and metabolic disorders [4] - The company also operates a commercial BioCosmeceutical platform, developing products that utilize cell-based secretome containing exosomes, proteins, and growth factors [6][7] Leadership and Strategy - Crystal Romano brings over 19 years of experience in the medical and regenerative industries, recognized for her expertise in product development, commercialization, and navigating FDA regulations [2] - The CEO of BioRestorative emphasized the importance of Romano's role at a critical time for the company, aiming to expand its commercial footprint and unlock revenue opportunities [3] Clinical Development Programs - The Disc/Spine Program includes BRTX-100, a cell therapy candidate derived from a patient's own mesenchymal stem cells, currently in Phase 2 clinical trials for chronic lower back pain [4] - The Metabolic Program, ThermoStem, focuses on using brown adipose-derived stem cells to target obesity and metabolic disorders, with promising preclinical research indicating potential benefits for weight loss and metabolic health [5] Future Directions - BioRestorative aims to expand its BioCosmeceutical offerings through IND-enabling studies, seeking to pioneer FDA approvals in the emerging market [7]

Accessibility StatementSkip Navigation TORONTO, Oct. 22, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology- driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced the signing of a strategic cooperation agreement with Jiangsu Yike Regenerative Medical Technology Co., Ltd. ("Yike") to jointly establish Visionary Yike Stemcell Technologies Inc., a Canada-based joint venture dedicated to advancing stem cell research, clinical application, and commercializ ...

Continue Reading Collink.3D (left image) exhibited skeletal Muscle elongation while Matrigel (right image) appeared non-uniform on day 7 (Technion) Matrigel®, developed and marketed by Corning, has been one of the most widely used extracellular matrices for more than three decades. Derived from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, it contains a rich combination of basement membrane proteins such as laminin, collagen IV, heparan sulfate proteoglycans, and entactin/nidogen, as well as growth factors ...

Adia Nutrition Paves Way for Nasdaq and New Investors Through SEC Form 10 SubmissionOctober 14, 2025 9:00 AM EDT | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - October 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is thrilled to announce a major milestone in its growth journey. The Company has engaged an independent public accounting firm and securities counsel to prepare and file its Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC). T ...

Julius Ladeira Appointed to Lead Market Entry into Latin America's Largest Healthcare Market; São Paulo Conference Scheduled for October 2-3, 2025 LAS VEGAS, NV / ACCESS Newswire / October 14, 2025 / Regenerative Medical Technologies Group, Inc. (OTCID:RMTG), a global leader in regenerative medicine solutions, today announced the expansion of its operations into Brazil through a strategic representation agreement with Julius Ladeira. The collaboration brings the full scope of RMTG's divisions-including ISSC ...

GV will leverage its international commercialization network, clinical collaboration channels, and operational expertise to introduce and expand the application of these technologies across global market. , /PRNewswire/ --Â Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology Licensing Agreement with Jian ...

Core Insights - Adia Nutrition Inc. reported a remarkable revenue increase of over 100% in the third quarter compared to the previous quarter, alongside a profit margin exceeding 20%, highlighting its strong position in the regenerative medicine industry driven by high demand for its therapies [1][6]. Financial Performance - Revenue surged by more than 100% from the second quarter, primarily due to increased sales of umbilical cord stem cells and exosomes through various channels including clinical partnerships and direct-to-consumer sales [6]. - The company achieved a profit margin exceeding 20%, reflecting operational efficiency and the success of its high-margin therapeutic offerings [6]. Strategic Positioning - The third quarter results signify a historic leap for Adia Nutrition, showcasing the company's commitment to redefining possibilities in the regenerative medicine sector [2]. - The company is positioned for record-breaking annual growth and enhanced shareholder value, building on its year-to-date success [6]. Business Model and Offerings - Adia Nutrition operates two main divisions: a supplement division focused on premium organic supplements and a medical division that specializes in advanced stem cell therapies, including Umbilical Cord Stem Cells and Autologous Hematopoietic Stem Cell Transplantation [5]. - The company is actively seeking strategic partnerships to expand access to its regenerative therapies [4].

Core Insights - Adia Nutrition Inc. has divested its Biolete coffee subsidiary to Cement Factory LLC while retaining an 18% ownership stake to maintain strategic alignment with Biolete's growth [1][4][5] - The divestiture allows Adia to focus on its core mission of expanding regenerative medicine and medical sales within the $5.3 trillion U.S. healthcare market [1][5][6] Company Strategy - The sale of Biolete, which specializes in organic protein and mushroom-infused coffee products, enables Adia to concentrate resources on scaling its medical division and enhancing its stem cell therapies [4][5] - Adia's CEO emphasized the transformative potential in medical treatments and regenerative therapies, indicating a strategic pivot towards these high-growth areas [5][6] Operational Developments - Adia has recently tripled its sales force and opened its first satellite clinic to expand access to regenerative treatments, reinforcing its commitment to community-based care [6] - The company has also improved its corporate governance by canceling over 25 million improperly issued shares, which enhances shareholder value and operational transparency [6] Future Outlook - Proceeds from the sale will be reinvested into the development of additional Adia Med clinics and R&D for next-generation therapies, positioning the company for future growth [7] - Cement Factory LLC, led by experienced entrepreneurs, is expected to drive Biolete's innovation and market expansion while collaborating with Adia on strategic initiatives [4][7]

Core Insights - The European Wellness Biomedical Group (EWBG) emphasizes that true longevity is achieved through cellular regeneration rather than organ transplantation, focusing on healthspan over lifespan [1][3][17] - Prof. Mike Chan's recent publications include the Human Cytology Atlas, which maps over 400 distinct human cell types, and a study on organ aging, highlighting the varying rates at which different organs age [1][11][24] Company Developments - EWBG has published significant scientific contributions, including the Human Cytology Atlas and a peer-reviewed study on organ aging, reinforcing its position in the field of regenerative medicine [1][10][24] - The company is involved in global collaborations, such as working with the Chinese government on autism therapies and ongoing research with Heidelberg University in Germany and Switzerland [14][24][25] Industry Trends - The conversation around longevity is shifting from organ transplantation to cellular regeneration, with a focus on targeted therapies that address the cellular mechanisms of aging [6][12][17] - Prof. Chan advocates for precision medicine that tailors interventions to individual cellular profiles, aiming to extend healthspan rather than merely increasing lifespan [13][21]

CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, November 6th. Management will host a conference call at 5:00 p.m. Eastern Time on November 6th to ...